Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for a change in the marketing license holder of its Epalrestat tablets. This approval is part of a broader agreement with Beijing Minkang Baicao Pharmaceutical Technology Company Limited, which involves the transfer of production technology and marketing authorization holder status for Mecobalamin tablets to Xinhua Pharmaceutical. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and operational capabilities in the pharmaceutical industry.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production and marketing of prescription drugs. The company focuses on the development and commercialization of various pharmaceutical products, including Mecobalamin tablets.
YTD Price Performance: -3.10%
Average Trading Volume: 2,170,030
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.56B
Find detailed analytics on 0719 stock on TipRanks’ Stock Analysis page.